Publication Type : Conference Proceedings
Publisher : Elsevier
Source : In ESMO 2021. https://doi.org/10.1016/j.annonc.2021.08.140
Url : https://www.sciencedirect.com/science/article/pii/S0923753421023541?via%3Dihub
Campus : Kochi
School : School of Medicine
Year : 2021
Abstract : Background Elevated amylase in Multiple myeloma (MM) was first described in 1988. It has been postulated that translocation of chromosome 1, where the amylase gene is situated is responsible for the ectopic production from the malignant plasma cells. Previous case reports have shown that patients with hyperamylasemia in MM are associated with extensive bone disease, rapid progression and shorter survival. The study was conducted to ascertain the degree of elevated amylase in MM patients.
Cite this Research Publication : C. Panthula, W.M. Jose, S. Krishnan. "847P The utility of serum amylase as a clinical marker in patients with multiple myeloma". In ESMO 2021. https://doi.org/10.1016/j.annonc.2021.08.140